期刊文献+

2014年上半年美国FDA批准药物简介 被引量:4

Overviews and analysis of the U.S. FDA′ s new approvals in 2014 first half year
下载PDF
导出
摘要 2014年上半年美国FDA批准46种新药(包括修改说明书,新剂型,新组方和其他),其中首次批准上市10个新分子实体和生物制品许可申请10个,共计20个。本文根据FDA批准的处方资料的要点,简要介绍新药概况、作用机制、适应证、剂量和用法、黑框警告、禁忌证、不良反应、药物相互作用及特殊人群中使用要点。并讨论了2014上半年批准新药在药物开发、研究和审评使中的首次事件。 In the first half of 2014, the U.S. Food and Drug Administration (FDA) approved 46 new drugs, including 10 new molecular entities and 10 new biologic license applications. According to the prescription information for professionals, this article introduces the description, mechanism of action and clinical studies, briefly describs the box warning, indications and usage, dosage and administration, dosage form and strength, contraindications, warning and precautions, adverse reactions, drug interaction and use in special population of these new drugs. In addition, the “first events” in the history of new drug research, development and approval are also discussed.
作者 汤仲明
出处 《国际药学研究杂志》 CAS CSCD 2014年第4期493-502,共10页 Journal of International Pharmaceutical Research
关键词 新药批准 美国FDA 新分子实体 新生物制品 化学结构 作用机制 适应证 不良反应 new drug approval the U.S. FDA new molecular entity new biological products chemical structure mech-anism indications adverse reactions
  • 相关文献

参考文献13

  • 1Drug.New drug approvala[EB/OL].(2014-06-29)[2014-07-08].http://www.drugs.com/.
  • 2US.FDA.New drug approvals [EB/OL](2014-06-29)[2014-07-08 ].http://www.fda.gov/.
  • 3European Medicines Agency.New drug approvals [EB/OL](2014-06-29)[ 2014-07-08 ].http://www.emea.europa.eu/htms/human/-epar/a.htm.
  • 4..汤教授新药信息和技术博客http://blog.sina.com.cn/u/1497903197,(2014-06-29)[2014-07-08].
  • 5Ramalingam SS,Khuri FR.Second-generation ALK inhibitors:fill-ing the non “MET” gap[j].Cancer Discov,2014,4(6):634-636.
  • 6Goldenberg MM.Pharmaceutical approval update[j].Pharm Ther,2014,39(4):262-296.
  • 7Fernandez OL,Diaz-Toro Y,Ovalle C,et al.Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia[J].PLoS Negl Trop Dis,2014,8(5):e2871.
  • 8Chen Y,Zervos MJ,Vazquez JA.Dalbavancin:a novel antimicro-bial[j].Int J Clin Pract,2007,61(5):853-863.
  • 9Lassen A,Atefi M,Robert L,et al.Effects of AKT inhibitor ther-apy in response and resistance to BRAF inhibition in melanoma[j].Mol Cancer,2014,16(13):83.
  • 10Reichert JM.Antibodies to watch in 2014 mid-year update [j].MAbs,2014,6(4):1-4.

同被引文献83

  • 1尹明,曾贱高,张华.医院感染的临床分布及耐药性的调查分析[J].实用预防医学,2006,13(2):312-313. 被引量:35
  • 2邹栩,顾凯.世界新药研发动向[J].中国新药杂志,2007,16(22):1821-1825. 被引量:5
  • 3VINH DC ,EMBIL JM. Rapidly progressive soft tissue infections[J]. Lancet Dis, 2005,5(8) ; 501 -513.
  • 4STEVENS DL, BISNO AL, CHEAMBERS HF, et al. Practiceguidelines for the diagnosis and management of skin and soft-tis-sue infections[ J]. Clin Infec Dis,2005,41 (10) : 1373 - 1406.
  • 5LECLERCQ Rf DERLOTE,DUVALJ,et al. Plasmid-mediatedresistance to vancomycin and T-eicoplanin in Enterococcusfaecium[J]. N Eng J Med, 1988,319(7) : 157 - 160.
  • 6UTTLEY AH, COLLINS CH, NAIDOO J, et al Vancomycin-re-sistant enterococci[ J]. Lancet, 1993,342(8871) : S67 -S68.
  • 7AKSOY DY,TANRIOVER MD,UNAL S. Antimicrobial resist-ance :preventable of inevitable. Problem of the era from two per-spectives [ C ]. Gould IM, vander Meer JWM. Antibiotic policies :fighting resistance. Nwe York : Springer, Septemberus, 2007: 113 -133.
  • 8MOELLERING RC JR. Discovering new antimicrobial agents[ J].Int J Antimicrob Agents, 2001,37 (1 ) : 2-9.
  • 9FORD CW,HAMEL JC, STAPERT D,et al. Oxazolidinones :new antibacterial agents [ J ]. Trends Microbiol,1997,5(5):196 -200.
  • 10MEAGHER AK, FORREST A, HAYNER CA,et al. Populationpharmacokinetics of linezoiid in patients treated in a compas2sionate-use program [ J ]. Antimicrob Agents Chemother, 2003,47(2): 548 -553.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部